PUT/VERTEX PHARMACEUTICALS/500/0.1/17.01.25 | Real-time BOERSE MUENCHEN 07:56:58 01/07/2024 pm IST | ||
| 4.04 EUR | -0.98% |
|
| Current month | -28.04% | ||
| 1 month | -28.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 4.04 | -0.98% |
| 28/24/28 | 4.08 | +0.74% |
| 27/24/27 | 4.05 | -0.25% |
| 26/24/26 | 4.06 | -0.25% |
| 25/24/25 | 4.07 | +0.25% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 07:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG1XE8 |
| ISIN | DE000GG1XE88 |
| Date issued | 05/01/2024 |
| Strike | 500 $ |
| Maturity | 17/01/2025 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 8.04 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.25 € |
|---|---|
| Lowest since issue | 3.68 € |
| Spread | 0.2 € |
| Spread % | 4.95% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
